Urogen rises on higher Q2 sales of its cancer drug

UroGen Pharma

10/08/2023 14:05

** U.S.-listed shares of Israeli drug developer UroGen
Pharma  URGN.O  rise 3.4% to $21.4 premarket
    ** Co reports Q2 sales of $21.1 mln for its cancer drug
Jelmyto, up 27.1% from last year   
    ** Jelmyto is used for treatment of a type of urinary tract
cancer
    ** Co posts Q2 net loss of $24.1 million, or $1.03/share, vs
loss of $26.7 million, or $1.18/share, a year earlier
    ** URGN reiterates annual forecast for Jelmyto sales of $76
mln-$86 mln
    ** Four of five brokerages covering the stock rate it "buy"
or higher and one rates it "hold"; their median PT is $42.5
-Refinitiv
    ** Up to last close, U.S.-listed shares have more than
doubled in value YTD 

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.in))